Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Potential treatment for E. coli disease

By R&D Editors | June 7, 2011

E. coli

The probiotic bacterium (blue) with E. coli Shiga toxin (red) bound all over its surface.

A potential life-saving treatment for severe E. coli food poisoning outbreaks—developed
more than a decade ago—hasn’t gone forward into clinical trials because of lack
of commercial interest.

Univ. of Adelaide researchers produced a
“designer” probiotic bacterium which binds and neutralizes the toxin
produced by E. coli, which
causes life-threatening attack on the kidneys and blood vessels.

The team of scientists—Dr Adrienne Paton, Associate Professor
Renato Morona, and Professor James Paton—showed that mice infected with a highly
virulent strain of E. coli
were completely protected by the probiotic bacterium.

The research was published in Nature
Medicine
in 2000 and generated ongoing interest from the scientific
and medical community—but the commercial sector hasn’t taken up its development
for progress into clinical trials in humans.

“Severe E. coli
food poisoning outbreaks such as that currently occurring in Europe are
becoming increasingly common,” said Professor Paton, Director, Research Center
for Infectious Diseases in the School of Molecular
and Biomedical Science.

“They have the potential to cause wide-spread disease and
many patients develop life-threatening complications including kidney failure.

“The probiotic bacterium could be produced cheaply on a
large scale. However, in spite of on-going attention from the scientific and
medical community, there has been a lack of interest from the commercial sector
in taking this product forward into clinical trials.

“If this had been done, and the probiotic had been proven
to be safe and efficacious in humans, it could have been deployed during the
current European outbreak. This would undoubtedly have saved lives, as well as
millions of dollars in current and future health care costs.”

The researchers engineered a harmless bacterium to mimic binding
receptors for the potentially fatal Shiga toxin on its surface.

Professor Paton said after diagnosis of E. coli
infection there was a window of opportunity for therapeutic intervention before
kidneys started to fail. Antibiotics are not used because they can increase the
amount of toxin released in the gut.

SOURCE

Related Articles Read More >

Floating solar mats clean polluted water — and generate power
New AI model offers faster, adaptive CO₂ retrieval from satellite data
8 major R&D moves this week: Samsung invests record $24B while Porsche cuts 3,900 jobs
Ex-Google AI team launches “Generation,” an AI-driven fragrance venture
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE